Trial Outcomes & Findings for A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults (NCT NCT04839562)
NCT ID: NCT04839562
Last Updated: 2024-03-04
Results Overview
Difference between active and placebo for change in Adult ADHD Investigator Symptom Rating total score from baseline to week 6 visit. The minimum score on this scale is 0, the maximum score for the scale is 54 points.Higher numbers indicate more ADHD symptoms, lower scores reflect lower ADHD symptoms.
COMPLETED
PHASE2/PHASE3
66 participants
six weeks
2024-03-04
Participant Flow
66 participants signed consent to participate in the study, per definition of enrollment. 6 of these participants ended up being excluded, and were never exposed (3 lost to follow up, 2 withdrew, 1 found to be ineligible after enrollment). 60 participants total were exposed to solriamfetol or placebo.
Participant milestones
| Measure |
Solriamfetol
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Solriamfetol 75 MG: Daily oral consumption
Solriamfetol 150 MG: Daily oral consumption
|
Placebo
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Placebo: Placebo
|
|---|---|---|
|
Overall Study
STARTED
|
29
|
31
|
|
Overall Study
COMPLETED
|
29
|
29
|
|
Overall Study
NOT COMPLETED
|
0
|
2
|
Reasons for withdrawal
| Measure |
Solriamfetol
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Solriamfetol 75 MG: Daily oral consumption
Solriamfetol 150 MG: Daily oral consumption
|
Placebo
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Placebo: Placebo
|
|---|---|---|
|
Overall Study
Withdrawal by Subject
|
0
|
1
|
|
Overall Study
Physician Decision
|
0
|
1
|
Baseline Characteristics
A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults
Baseline characteristics by cohort
| Measure |
Solriamfetol
n=29 Participants
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Solriamfetol 75 MG: Daily oral consumption
Solriamfetol 150 MG: Daily oral consumption
|
Placebo
n=31 Participants
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Placebo: Placebo
|
Total
n=60 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
36.2 years
n=99 Participants
|
36.9 years
n=107 Participants
|
36.6 years
n=206 Participants
|
|
Sex/Gender, Customized
Male
|
10 Participants
n=99 Participants
|
17 Participants
n=107 Participants
|
27 Participants
n=206 Participants
|
|
Sex/Gender, Customized
Female
|
17 Participants
n=99 Participants
|
12 Participants
n=107 Participants
|
29 Participants
n=206 Participants
|
|
Sex/Gender, Customized
Other
|
2 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
4 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
4 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
6 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
25 Participants
n=99 Participants
|
29 Participants
n=107 Participants
|
54 Participants
n=206 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Asian
|
3 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
5 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
5 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
7 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Black or African American
|
2 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
4 Participants
n=206 Participants
|
|
Race (NIH/OMB)
White
|
19 Participants
n=99 Participants
|
25 Participants
n=107 Participants
|
44 Participants
n=206 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Highest Education
High School Graduate
|
1 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
|
Highest Education
Some college but no college degree
|
4 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
6 Participants
n=206 Participants
|
|
Highest Education
Associate's Degree
|
2 Participants
n=99 Participants
|
3 Participants
n=107 Participants
|
5 Participants
n=206 Participants
|
|
Highest Education
Bachelor's or RN Degree
|
10 Participants
n=99 Participants
|
16 Participants
n=107 Participants
|
26 Participants
n=206 Participants
|
|
Highest Education
Some graduate school but no graduate degree
|
2 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
4 Participants
n=206 Participants
|
|
Highest Education
Master's Degree
|
3 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
5 Participants
n=206 Participants
|
|
Highest Education
Doctoral or Law Degree
|
7 Participants
n=99 Participants
|
6 Participants
n=107 Participants
|
13 Participants
n=206 Participants
|
|
Marital Status
Married
|
13 Participants
n=99 Participants
|
12 Participants
n=107 Participants
|
25 Participants
n=206 Participants
|
|
Marital Status
Unmarried
|
16 Participants
n=99 Participants
|
19 Participants
n=107 Participants
|
35 Participants
n=206 Participants
|
|
Socioeconomic Status
|
98349 Dollars
STANDARD_DEVIATION 31349 • n=99 Participants
|
119593 Dollars
STANDARD_DEVIATION 33612 • n=107 Participants
|
109325 Dollars
STANDARD_DEVIATION 34041 • n=206 Participants
|
|
Clinical Global Impressions Severity (Baseline)
4 Moderately Ill
|
22 Participants
n=99 Participants
|
25 Participants
n=107 Participants
|
47 Participants
n=206 Participants
|
|
Clinical Global Impressions Severity (Baseline)
5 Markedly Ill
|
7 Participants
n=99 Participants
|
6 Participants
n=107 Participants
|
13 Participants
n=206 Participants
|
|
Global Assessment of Functioning Scale Score (Baseline)
|
63.8 total score on a scale
n=99 Participants
|
63.8 total score on a scale
n=107 Participants
|
63.8 total score on a scale
n=206 Participants
|
PRIMARY outcome
Timeframe: six weeksDifference between active and placebo for change in Adult ADHD Investigator Symptom Rating total score from baseline to week 6 visit. The minimum score on this scale is 0, the maximum score for the scale is 54 points.Higher numbers indicate more ADHD symptoms, lower scores reflect lower ADHD symptoms.
Outcome measures
| Measure |
Solriamfetol
n=29 Participants
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Solriamfetol 75 MG: Daily oral consumption
Solriamfetol 150 MG: Daily oral consumption
|
Placebo
n=31 Participants
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Placebo: Placebo
|
|---|---|---|
|
Adult Attention Deficit Hyperactivity Disorder (ADHD) Investigator Symptom Rating Scale (AISRS) Total Score
|
-7.6 score on a scale
Interval -9.9 to -5.3
|
-2.1 score on a scale
Interval -4.4 to 0.2
|
PRIMARY outcome
Timeframe: six weeks25% reduction in ADHD symptoms as measured by the Adult ADHD Investigator Symptom Rating Scale (AISRS), and a Clinical Global Impression Improvement score of 2 (much) or 1 (very much) improved. The minimum score on the AISRS scale is 0, the maximum score for the scale is 54 points.Higher numbers indicate more ADHD symptoms, lower scores reflect lower ADHD symptoms. The Clinical Global Impression (CGI) Improvement scores range from 0 to 7, with 0=not assessed,1=very much improved), 2=much improved, through to 7=very much worse. Lower scores therefore mean better outcomes.
Outcome measures
| Measure |
Solriamfetol
n=29 Participants
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Solriamfetol 75 MG: Daily oral consumption
Solriamfetol 150 MG: Daily oral consumption
|
Placebo
n=31 Participants
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Placebo: Placebo
|
|---|---|---|
|
A Priori Definition of Clinical Improvement
|
13 Participants
|
2 Participants
|
SECONDARY outcome
Timeframe: 6 weeksWe secondarily will explore whether there are reduced symptoms of executive dysfunction (defined by a 0.5 standard deviation improvement on the Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A) self-report total (GEC). The BRIEF has 75 items that are rated in terms of frequency on a 3-point scale: 0 (never), 1 (sometimes), 2 (often). The range of scores is 0 to 225. Ther are 9 subscales that are indexed under two categories, Behavioral Regulation (BRI) and Metacognition (MI), and these indexes form the overall summary score, the Global Executive Composite (GEC). Raw scores for each scale are summed and T scores (M = 50, SD = 10) are used to interpret the individual's level of executive functioning. Higher scores reflect worse functioning, and lower scores reflect better functioning.
Outcome measures
| Measure |
Solriamfetol
n=29 Participants
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Solriamfetol 75 MG: Daily oral consumption
Solriamfetol 150 MG: Daily oral consumption
|
Placebo
n=29 Participants
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Placebo: Placebo
|
|---|---|---|
|
Number of Participants Reaching 0.5 Standard Deviation Improvement on Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A): Global Executive Composite Index
|
20 Participants
|
10 Participants
|
SECONDARY outcome
Timeframe: 6 weeksWe secondarily will explore whether there are reduced symptoms of executive dysfunction (defined by a 0.5 standard deviation improvement on the Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A) self-report total (GEC) or subscale scores. The BRIEF has 75 items that are rated in terms of frequency on a 3-point scale: 0 (never), 1 (sometimes), 2 (often). The range of scores is 0 to 225. There are 9 subscales that are indexed under two categories, one of which is Behavioral Regulation (BRI). The raw score of the BRI is converted into a T scores (M = 50, SD = 10) are used to interpret the individual's level of executive functioning. Higher scores reflect worse functioning, and lower scores reflect better functioning.
Outcome measures
| Measure |
Solriamfetol
n=29 Participants
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Solriamfetol 75 MG: Daily oral consumption
Solriamfetol 150 MG: Daily oral consumption
|
Placebo
n=29 Participants
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Placebo: Placebo
|
|---|---|---|
|
Number of Participants Reaching 0.5 Standard Deviation Improvement on Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A): Behavioral Regulation Index
|
18 Participants
|
11 Participants
|
SECONDARY outcome
Timeframe: 6 weeksWe secondarily will explore whether there are reduced symptoms of executive dysfunction (defined by a 0.5 standard deviation improvement on the Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A) self-report total (GEC) or subscale scores). The BRIEF has 75 items that are rated in terms of frequency on a 3-point scale: 0 (never), 1 (sometimes), 2 (often). The range of scores is 0 to 225. There are 9 subscales that are indexed under two categories, one of which is Metacognition Index (MI). The raw score of the MI is converted into a T scores (M = 50, SD = 10) are used to interpret the individual's level of executive functioning. Higher scores reflect worse functioning, and lower scores reflect better functioning.
Outcome measures
| Measure |
Solriamfetol
n=29 Participants
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Solriamfetol 75 MG: Daily oral consumption
Solriamfetol 150 MG: Daily oral consumption
|
Placebo
n=29 Participants
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Placebo: Placebo
|
|---|---|---|
|
Number of Participants Reaching 0.5 Standard Deviation Improvement on Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A): Metacognition Index
|
19 Participants
|
10 Participants
|
SECONDARY outcome
Timeframe: 6 weeksWe secondarily will explore whether there are reduced symptoms of executive dysfunction (defined by a 0.5 standard deviation improvement on the Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A) self-report total (GEC) or subscale scores). The BRIEF has 75 items that are rated in terms of frequency on a 3-point scale: 0 (never), 1 (sometimes), 2 (often). The range of scores is 0 to 225. There are 9 subscales, one of which is the Inhibit subscale. Raw scores for this scale are summed and T scores (M = 50, SD = 10) are used to interpret the individual's level of executive functioning. Higher scores reflect worse functioning, and lower scores reflect better functioning.
Outcome measures
| Measure |
Solriamfetol
n=29 Participants
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Solriamfetol 75 MG: Daily oral consumption
Solriamfetol 150 MG: Daily oral consumption
|
Placebo
n=29 Participants
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Placebo: Placebo
|
|---|---|---|
|
Number of Participants Reaching 0.5 Standard Deviation Improvement on Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A): Inhibit Subscale
|
11 Participants
|
10 Participants
|
SECONDARY outcome
Timeframe: 6 weeksWe secondarily will explore whether there are reduced symptoms of executive dysfunction (defined by a 0.5 standard deviation improvement on the Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A) self-report total (GEC) or subscale scores). The BRIEF has 75 items that are rated in terms of frequency on a 3-point scale: 0 (never), 1 (sometimes), 2 (often). The range of scores is 0 to 225. Ther are 9 subscales that are indexed under two categories, one of which is the Shift subscale. Raw scores for this scale are summed and T scores (M = 50, SD = 10) are used to interpret the individual's level of executive functioning. Higher scores reflect worse functioning, and lower scores reflect better functioning.
Outcome measures
| Measure |
Solriamfetol
n=29 Participants
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Solriamfetol 75 MG: Daily oral consumption
Solriamfetol 150 MG: Daily oral consumption
|
Placebo
n=29 Participants
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Placebo: Placebo
|
|---|---|---|
|
Number of Participants Reaching 0.5 Standard Deviation Improvement on Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A): Shift Subscale
|
20 Participants
|
10 Participants
|
SECONDARY outcome
Timeframe: 6 weeksWe secondarily will explore whether there are reduced symptoms of executive dysfunction (defined by a 0.5 standard deviation improvement on the Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A) self-report total (GEC) or subscale scores). The BRIEF has 75 items that are rated in terms of frequency on a 3-point scale: 0 (never), 1 (sometimes), 2 (often). The range of scores is 0 to 225. There are 9 subscales, one of which is the Emotional Control subscale. Raw scores for this scale are summed and T scores (M = 50, SD = 10) are used to interpret the individual's level of executive functioning. Higher scores reflect worse functioning, and lower scores reflect better functioning.
Outcome measures
| Measure |
Solriamfetol
n=29 Participants
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Solriamfetol 75 MG: Daily oral consumption
Solriamfetol 150 MG: Daily oral consumption
|
Placebo
n=29 Participants
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Placebo: Placebo
|
|---|---|---|
|
Number of Participants Reaching 0.5 Standard Deviation Improvement on Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A): Emotional Control Subscale
|
16 Participants
|
10 Participants
|
SECONDARY outcome
Timeframe: 6 weeksWe secondarily will explore whether there are reduced symptoms of executive dysfunction (defined by a 0.5 standard deviation improvement on the Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A) self-report total (GEC) or subscale scores). The BRIEF has 75 items that are rated in terms of frequency on a 3-point scale: 0 (never), 1 (sometimes), 2 (often). The range of scores is 0 to 225. There are 9 subscales, one of which is the Self-Monitor subscale. Raw scores for this scale are summed and T scores (M = 50, SD = 10) are used to interpret the individual's level of executive functioning. Higher scores reflect worse functioning, and lower scores reflect better functioning.
Outcome measures
| Measure |
Solriamfetol
n=29 Participants
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Solriamfetol 75 MG: Daily oral consumption
Solriamfetol 150 MG: Daily oral consumption
|
Placebo
n=29 Participants
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Placebo: Placebo
|
|---|---|---|
|
Number of Participants Reaching 0.5 Standard Deviation Improvement on Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A): Self-Monitor Subscale
|
13 Participants
|
9 Participants
|
SECONDARY outcome
Timeframe: 6 weeksWe secondarily will explore whether there are reduced symptoms of executive dysfunction (defined by a 0.5 standard deviation improvement on the Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A) self-report total (GEC) or subscale scores). The BRIEF has 75 items that are rated in terms of frequency on a 3-point scale: 0 (never), 1 (sometimes), 2 (often). The range of scores is 0 to 225. There are 9 subscales, one of which is the Initiate subscale. Raw scores for this scale are summed and T scores (M = 50, SD = 10) are used to interpret the individual's level of executive functioning. Higher scores reflect worse functioning, and lower scores reflect better functioning.
Outcome measures
| Measure |
Solriamfetol
n=29 Participants
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Solriamfetol 75 MG: Daily oral consumption
Solriamfetol 150 MG: Daily oral consumption
|
Placebo
n=29 Participants
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Placebo: Placebo
|
|---|---|---|
|
Number of Participants Reaching 0.5 Standard Deviation Improvement on Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A): Initiate Subscale
|
18 Participants
|
9 Participants
|
SECONDARY outcome
Timeframe: 6 weeksWe secondarily will explore whether there are reduced symptoms of executive dysfunction (defined by a 0.5 standard deviation improvement on the Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A) self-report total (GEC) or subscale scores) The BRIEF has 75 items that are rated in terms of frequency on a 3-point scale: 0 (never), 1 (sometimes), 2 (often). The range of scores is 0 to 225. There are 9 subscales, one of which is the Working Memory subscale. Raw scores for this scale are summed and T scores (M = 50, SD = 10) are used to interpret the individual's level of executive functioning. Higher scores reflect worse functioning, and lower scores reflect better functioning.
Outcome measures
| Measure |
Solriamfetol
n=29 Participants
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Solriamfetol 75 MG: Daily oral consumption
Solriamfetol 150 MG: Daily oral consumption
|
Placebo
n=29 Participants
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Placebo: Placebo
|
|---|---|---|
|
Number of Participants Reaching 0.5 Standard Deviation Improvement on Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A): Working Memory Subscale
|
17 Participants
|
9 Participants
|
SECONDARY outcome
Timeframe: 6 weeksWe secondarily will explore whether there are reduced symptoms of executive dysfunction (defined by a 0.5 standard deviation improvement on the Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A) self-report total (GEC) or subscale scores). The BRIEF has 75 items that are rated in terms of frequency on a 3-point scale: 0 (never), 1 (sometimes), 2 (often). The range of scores is 0 to 225. There are 9 subscales, one of which is the Plan/Organize subscale. Raw scores for this scale are summed and T scores (M = 50, SD = 10) are used to interpret the individual's level of executive functioning. Higher scores reflect worse functioning, and lower scores reflect better functioning.
Outcome measures
| Measure |
Solriamfetol
n=29 Participants
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Solriamfetol 75 MG: Daily oral consumption
Solriamfetol 150 MG: Daily oral consumption
|
Placebo
n=29 Participants
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Placebo: Placebo
|
|---|---|---|
|
Number of Participants Reaching 0.5 Standard Deviation Improvement on Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A): Plan/Organize Subscale
|
19 Participants
|
11 Participants
|
SECONDARY outcome
Timeframe: 6 weeksWe secondarily will explore whether there are reduced symptoms of executive dysfunction (defined by a 0.5 standard deviation improvement on the Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A) self-report total (GEC) or subscale scores). The BRIEF has 75 items that are rated in terms of frequency on a 3-point scale: 0 (never), 1 (sometimes), 2 (often). The range of scores is 0 to 225. There are 9 subscales, one of which is the Task Monitor subscale. Raw scores for this scale are summed and T scores (M = 50, SD = 10) are used to interpret the individual's level of executive functioning. Higher scores reflect worse functioning, and lower scores reflect better functioning.
Outcome measures
| Measure |
Solriamfetol
n=29 Participants
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Solriamfetol 75 MG: Daily oral consumption
Solriamfetol 150 MG: Daily oral consumption
|
Placebo
n=29 Participants
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Placebo: Placebo
|
|---|---|---|
|
Number of Participants Reaching 0.5 Standard Deviation Improvement on Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A): Task Monitor Subscale
|
18 Participants
|
11 Participants
|
SECONDARY outcome
Timeframe: 6 weeksWe secondarily will explore whether there are reduced symptoms of executive dysfunction (defined by a 0.5 standard deviation improvement on the Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A) self-report total (GEC) or subscale scores). The BRIEF has 75 items that are rated in terms of frequency on a 3-point scale: 0 (never), 1 (sometimes), 2 (often). The range of scores is 0 to 225. There are 9 subscales, one of which is the Organization of Materials subscale. Raw scores for this scale are summed and T scores (M = 50, SD = 10) are used to interpret the individual's level of executive functioning. Higher scores reflect worse functioning, and lower scores reflect better functioning.
Outcome measures
| Measure |
Solriamfetol
n=29 Participants
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Solriamfetol 75 MG: Daily oral consumption
Solriamfetol 150 MG: Daily oral consumption
|
Placebo
n=29 Participants
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Placebo: Placebo
|
|---|---|---|
|
Number of Participants Reaching 0.5 Standard Deviation Improvement on Brief Rating Inventory of Executive Function-Adult Version (BRIEF-A): Organization of Materials Subscale
|
14 Participants
|
9 Participants
|
Adverse Events
Solriamfetol
Placebo
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Solriamfetol
n=29 participants at risk
Participant will receive daily doses of solriamfetol, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Solriamfetol 75 MG: Daily oral consumption
Solriamfetol 150 MG: Daily oral consumption
|
Placebo
n=31 participants at risk
Participant will receive daily doses of placebo, at 75 mg at week one and 150 mg at week 2, and with intention that dosing remain stable for the last four weeks of study participation, such that investigators will ask a subject to go back down to 75 mg during any of the weeks following week 2 only if only if 150 mg is not tolerated.
Placebo: Placebo
|
|---|---|---|
|
Infections and infestations
Cold/Infection/Allergy
|
44.8%
13/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
54.8%
17/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
|
Metabolism and nutrition disorders
Increased Appetite
|
0.00%
0/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
3.2%
1/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
|
Metabolism and nutrition disorders
Decreased Appetite
|
17.2%
5/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
6.5%
2/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
|
General disorders
Headache
|
48.3%
14/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
29.0%
9/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
|
Gastrointestinal disorders
Nausea/Vomiting/Diarrhea (Gastrointestinal)
|
24.1%
7/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
6.5%
2/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
|
General disorders
Insomnia
|
31.0%
9/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
16.1%
5/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
|
General disorders
Sedation
|
10.3%
3/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
3.2%
1/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
|
General disorders
Increased Energy
|
13.8%
4/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
3.2%
1/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
|
Cardiac disorders
Cardiovascular
|
17.2%
5/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
3.2%
1/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
|
General disorders
Tense/jittery
|
3.4%
1/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
0.00%
0/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
|
General disorders
Agitated/irritable
|
10.3%
3/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
6.5%
2/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
|
Psychiatric disorders
Anxious/Worried
|
0.00%
0/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
3.2%
1/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
|
Gastrointestinal disorders
Mucosal Dryness
|
10.3%
3/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
12.9%
4/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
|
General disorders
Dizzy/Lightheaded
|
3.4%
1/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
0.00%
0/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
|
Nervous system disorders
Neurological
|
13.8%
4/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
3.2%
1/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal
|
24.1%
7/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
22.6%
7/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
|
Renal and urinary disorders
Genitourinary
|
10.3%
3/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
6.5%
2/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
|
Skin and subcutaneous tissue disorders
Dermtological
|
3.4%
1/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
12.9%
4/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
|
General disorders
Other
|
3.4%
1/29 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
9.7%
3/31 • Baseline to endpoint (6 weeks)
Adverse events were reported at weekly study visits or spontaneously by subjects
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place